GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ofirnoflast   Click here for help

GtoPdb Ligand ID: 13227

Synonyms: example 10 [WO2021242505] | HT-6184 | HT6184
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The chemical structure for ofirnoflast was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a serine/ threonine-protein kinase NIMA related kinase 7 (NEK7) inhibitor with anti-inflammatory potential. It is one of the examples claimed in Halia Therapeutics' patent WO2021242505A1 [1]. NEK7 inhibitors are being explored for anti-inflammatory activity that is mediated via inhibition of NLRP3 inflammasome activation thereby leading to reduced production of the pro-inflammatory cytokines IL-1β and IL-18. Halia Therapeutics have several NEK7 inhibitors in their development pipeline, the most advanced of which is HT-6184 (phase 2 for inflammatory pain). The only confirmation that aligns ofirnoflast with the company code HT-6184 that we have found is with the use of ofirnoflast as 'other names' in clinical trial records (March 2026). This 2026 article that describes ofirnoflast's binding mode, and in vitro and in vivo characteristics does not disclose its chemical structure or synonym [2]. It does however reveal that ofirnoflast engages an allosteric site adjacent to the enzymes ATP-binding pocket.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 116.7
Molecular weight 501.44
XLogP 2.17
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=C(C=C1C2=CN(C3CC3)C4=C2C(=NC=N4)N)F)NC(=O)NC5=NOC(=C5)C6(CC6)C(F)(F)F
Isomeric SMILES NC=1C2=C(N=CN1)N(C=C2C3=CC(=C(C=C3)NC(=O)NC4=NOC(=C4)C5(CC5)C(F)(F)F)F)C6CC6
InChI InChI=1S/C23H19F4N7O2/c24-14-7-11(13-9-34(12-2-3-12)20-18(13)19(28)29-10-30-20)1-4-15(14)31-21(35)32-17-8-16(36-33-17)22(5-6-22)23(25,26)27/h1,4,7-10,12H,2-3,5-6H2,(H2,28,29,30)(H2,31,32,33,35)
InChI Key MJUUWYZZPRAKCW-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

Immunopharmacology Comments
Small molecule inhibitors that directly target NEK7 to downregulate the inflammatory response modulated by the NLRP3 inflammasome (to abolish production of the pro-inflammatory cytokines IL-1β and IL-18) offer potential to treat inflammation-mediated pathology, either as therapeutics or prophylactics. Ofirnoflast binding to NEK7 disrupts its scaffolding function in NLRP3 inflammasome assembly, and validates NEK7 as a druggable checkpoint for NLRP3 inflammasome control with utility for the treatment of inflammation driven by inflammasome hyper-activation.